These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

252 related items for PubMed ID: 28669849

  • 1. Programmed Death Ligand 1 Expression in Paired Non-Small Cell Lung Cancer Tumor Samples.
    Cho JH, Sorensen SF, Choi YL, Feng Y, Kim TE, Choi H, Georgsen JB, Dolled-Filhart M, Emancipator K, Meldgaard P, Sun JM, Kim HK, Choi YS, Shim YM, Zhou W, Hager H, Kim J.
    Clin Lung Cancer; 2017 Nov; 18(6):e473-e479. PubMed ID: 28669849
    [Abstract] [Full Text] [Related]

  • 2. Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients.
    Ilie M, Juco J, Huang L, Hofman V, Khambata-Ford S, Hofman P.
    Cancer Cytopathol; 2018 Apr; 126(4):264-274. PubMed ID: 29411536
    [Abstract] [Full Text] [Related]

  • 3. Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer.
    Büttner R, Gosney JR, Skov BG, Adam J, Motoi N, Bloom KJ, Dietel M, Longshore JW, López-Ríos F, Penault-Llorca F, Viale G, Wotherspoon AC, Kerr KM, Tsao MS.
    J Clin Oncol; 2017 Dec 01; 35(34):3867-3876. PubMed ID: 29053400
    [Abstract] [Full Text] [Related]

  • 4. Programmed Cell Death Ligand 1 Expression in Resected Non-Small Cell Lung Cancer.
    Yu H, Brustugun OT, Ekman S, Botling J, La Fleur L, Micke P, Solberg S, Berglund A, Rivard C, Hirsch FR.
    Clin Lung Cancer; 2021 Jul 01; 22(4):e555-e562. PubMed ID: 33214079
    [Abstract] [Full Text] [Related]

  • 5. Retrospective Molecular Epidemiology Study of PD-L1 Expression in Patients with EGFR-Mutant Non-small Cell Lung Cancer.
    Cho JH, Zhou W, Choi YL, Sun JM, Choi H, Kim TE, Dolled-Filhart M, Emancipator K, Rutkowski MA, Kim J.
    Cancer Res Treat; 2018 Jan 01; 50(1):95-102. PubMed ID: 28301925
    [Abstract] [Full Text] [Related]

  • 6. Association of PD-L1 expression and PD-L1 gene polymorphism with poor prognosis in lung adenocarcinoma and squamous cell carcinoma.
    Yeo MK, Choi SY, Seong IO, Suh KS, Kim JM, Kim KH.
    Hum Pathol; 2017 Oct 01; 68():103-111. PubMed ID: 28851662
    [Abstract] [Full Text] [Related]

  • 7. Comparison of 22C3 PD-L1 Expression between Surgically Resected Specimens and Paired Tissue Microarrays in Non-Small Cell Lung Cancer.
    Li C, Huang C, Mok TS, Zhuang W, Xu H, Miao Q, Fan X, Zhu W, Huang Y, Lin X, Jiang K, Hu D, Chen X, Huang P, Lin G.
    J Thorac Oncol; 2017 Oct 01; 12(10):1536-1543. PubMed ID: 28751245
    [Abstract] [Full Text] [Related]

  • 8. Reliability of Small Biopsy Samples Compared With Resected Specimens for the Determination of Programmed Death-Ligand 1 Expression in Non--Small-Cell Lung Cancer.
    Kitazono S, Fujiwara Y, Tsuta K, Utsumi H, Kanda S, Horinouchi H, Nokihara H, Yamamoto N, Sasada S, Watanabe S, Asamura H, Tamura T, Ohe Y.
    Clin Lung Cancer; 2015 Sep 01; 16(5):385-90. PubMed ID: 25937270
    [Abstract] [Full Text] [Related]

  • 9. Association of Lung Adenocarcinoma Subtypes According to the IASLC/ATS/ERS Classification and Programmed Cell Death Ligand 1 (PD-L1) Expression in Tumor Cells.
    Cruz-Rico G, Avilés-Salas A, Popa-Navarro X, Lara-Mejía L, Catalán R, Sánchez-Reyes R, López-Sánchez D, Cabrera-Miranda L, Aquiles Maldonado-Martínez H, Samtani-Bassarmal S, Arrieta O.
    Pathol Oncol Res; 2021 Sep 01; 27():597499. PubMed ID: 34257548
    [Abstract] [Full Text] [Related]

  • 10. Dynamic changes in PD-L1 expression and CD8+ T cell infiltration in non-small cell lung cancer following chemoradiation therapy.
    Choe EA, Cha YJ, Kim JH, Pyo KH, Hong MH, Park SY, Shim HS, Jung I, Lee CY, Cho BC, Kim HR.
    Lung Cancer; 2019 Oct 01; 136():30-36. PubMed ID: 31421259
    [Abstract] [Full Text] [Related]

  • 11. Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations.
    Noll B, Wang WL, Gong Y, Zhao J, Kalhor N, Prieto V, Staerkel G, Roy-Chowdhuri S.
    Cancer Cytopathol; 2018 May 01; 126(5):342-352. PubMed ID: 29499101
    [Abstract] [Full Text] [Related]

  • 12. A prospective observational study to assess PD-L1 expression in small biopsy samples for non-small-cell lung cancer.
    Tsunoda A, Morikawa K, Inoue T, Miyazawa T, Hoshikawa M, Takagi M, Mineshita M.
    BMC Cancer; 2019 Jun 07; 19(1):546. PubMed ID: 31174496
    [Abstract] [Full Text] [Related]

  • 13. Real-world PD-L1 testing and distribution of PD-L1 tumor expression by immunohistochemistry assay type among patients with metastatic non-small cell lung cancer in the United States.
    Velcheti V, Patwardhan PD, Liu FX, Chen X, Cao X, Burke T.
    PLoS One; 2018 Jun 07; 13(11):e0206370. PubMed ID: 30408065
    [Abstract] [Full Text] [Related]

  • 14. Consistency of tumor and immune cell programmed cell death ligand-1 expression within and between tumor blocks using the VENTANA SP263 assay.
    Scorer P, Scott M, Lawson N, Ratcliffe MJ, Barker C, Rebelatto MC, Walker J.
    Diagn Pathol; 2018 Jul 24; 13(1):47. PubMed ID: 30041679
    [Abstract] [Full Text] [Related]

  • 15. Heterogeneity of Tumor and Immune Cell PD-L1 Expression and Lymphocyte Counts in Surgical NSCLC Samples.
    Casadevall D, Clavé S, Taus Á, Hardy-Werbin M, Rocha P, Lorenzo M, Menéndez S, Salido M, Albanell J, Pijuan L, Arriola E.
    Clin Lung Cancer; 2017 Nov 24; 18(6):682-691.e5. PubMed ID: 28549836
    [Abstract] [Full Text] [Related]

  • 16. Programmed death-ligand 1 expression on direct Pap-stained cytology smears from non-small cell lung cancer: Comparison with cell blocks and surgical resection specimens.
    Lozano MD, Abengozar-Muela M, Echeveste JI, Subtil JC, Bertó J, Gúrpide A, Calvo A, de Andrea CE.
    Cancer Cytopathol; 2019 Jul 24; 127(7):470-480. PubMed ID: 31245924
    [Abstract] [Full Text] [Related]

  • 17. MYC expression correlates with PD-L1 expression in non-small cell lung cancer.
    Kim EY, Kim A, Kim SK, Chang YS.
    Lung Cancer; 2017 Aug 24; 110():63-67. PubMed ID: 28676221
    [Abstract] [Full Text] [Related]

  • 18. Comparison of PD-L1 mRNA Expression Measured with the CheckPoint Typer® Assay with PD-L1 Protein Expression Assessed with Immunohistochemistry in Non-small Cell Lung Cancer.
    Erber R, Stöhr R, Herlein S, Giedl C, Rieker RJ, Fuchs F, Ficker JH, Hartmann A, Veltrup E, Wirtz RM, Brueckl WM.
    Anticancer Res; 2017 Dec 24; 37(12):6771-6778. PubMed ID: 29187455
    [Abstract] [Full Text] [Related]

  • 19. Programmed death-ligand 1 expression and T790M status in EGFR-mutant non-small cell lung cancer.
    Hata A, Katakami N, Nanjo S, Okuda C, Kaji R, Masago K, Fujita S, Yoshida H, Zama K, Imai Y, Hirata Y.
    Lung Cancer; 2017 Sep 24; 111():182-189. PubMed ID: 28838391
    [Abstract] [Full Text] [Related]

  • 20. The Prognostic Value of Measuring PD-L1 mRNA Expression Levels in Surgically Resected Non-Small Cell Lung Cancer.
    Kim GJ, Lee JH, Park WJ, Lee HW, Hwang IS, Lee DH.
    Ann Clin Lab Sci; 2019 May 24; 49(3):317-323. PubMed ID: 31308030
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.